论文部分内容阅读
目的对我所１９９５年５月～１９９８年５月２２例难治性恶性淋巴瘤疗效分析。方法采用ＩＭＶｐ１６方案联合顺铂治疗难治性恶性淋巴瘤２２例。其中Ｂ细胞１４例，Ｔ细胞４例，霍奇金病４例。恶性程度均为中～高度，分期为Ⅱ～Ⅳ期。结果治疗结果ＣＲ９例，占４０９％。ＰＲ８例，占３６４％。有效率为７７３％。主要毒性为骨髓抑制，白细胞减少Ⅲ～Ⅳ度为４５５％。胃肠道反应率４０９％。结论ＩＭＶｐ１６方案联合ＤＤＰ化疗治疗难治性恶性淋巴瘤是较有效且安全的方案。
Objective To analyze the therapeutic effect of 22 cases of refractory lymphoma in our hospital from May 1995 to May 1998. Methods Twenty-two patients with refractory lymphoma were treated with IMVp16 regimen and cisplatin. Among them, 14 cases were B cells, 4 cases were T cells, and 4 cases were Hodgkin's disease. The degree of malignancy is medium to high and the stage is II to IV. Results The results of treatment CR9 cases, accounting for 40.9%. PR8 cases accounted for 36.4%. The effective rate is 77. 3%. The main toxicity was myelosuppression. The leukopenia was 45 to 5% in the degree III to IV. The gastrointestinal response rate was 40.9%. Conclusion IMVp16 regimen combined with DDP chemotherapy is an effective and safe treatment for refractory lymphoma.